Risankizumab

Continuity Biosciences, LLC launches to develop advanced technologies for cell reprogramming, immune modulation, and drug delivery, aiming to enhance therapies for chronic diseases. Founded by experienced scientists and industry leaders, the company plans to expand its technology portfolio for diverse treatment delivery strategies.

Biosimilars face barriers in the US, including the patent system, interchangeability, and PBM policies. The 'patent dance' under the BPCIA aims to expedite biosimilar market entry but is criticized for being cumbersome. Patent litigation often leads to biosimilar launch delays, as seen with adalimumab and ustekinumab biosimilars. Policy reforms, such as the Affordable Prescriptions for Patients Act, aim to address these issues but face legislative challenges.

The biopharmaceutical sector rebounded in Q3 2024, with top 20 companies seeing a 2% increase in market capitalization to $4.3 trillion. Bristol-Myers Squibb led with a 24.6% surge, driven by FDA approval of Cobenfy. Gilead Sciences rose 22.1% due to accelerated approvals for Livdelzi and Trodelvy. Sanofi's market cap jumped 19.2% on Dupixent's success. AbbVie gained 15.2% from immunology drugs. Alnylam Pharmaceuticals and Roche Holdings also saw significant growth. Novo Nordisk, Eli Lilly, and Merck faced declines.

Skyrizi surpasses Humira in sales, causing concerns for adalimumab biosimilar market growth. Despite biosimilars capturing 22% market share by Oct 2024, Skyrizi's rise and product hopping complicate biosimilar sustainability. Clinical trials show Skyrizi's superior efficacy in psoriasis treatment, and policy reforms are advocated to enhance biosimilar access and competition.

Skyrizi sales surpass Humira for the first time in Q3 2024, with Skyrizi sales up 50.8% to $3.205 billion and Humira down 37.2% to $2.227 billion. This shift is attributed to the rise of Skyrizi and Rinvoq, impacting adalimumab biosimilar market share despite their growth.

Top 20 biopharmaceutical companies saw a 2% market cap increase in Q3 2024, driven by FDA approvals and strategic alliances. Bristol Myers Squibb led with a 24.6% growth, fueled by Cobenfy's approval and a $3.5bn deal with Prime Medicine. Gilead Sciences and Sanofi also grew significantly due to new drug approvals. Despite some declines, industry recovery is expected, supported by Federal Reserve interest rate cuts.